» Articles » PMID: 34177968

Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment

Overview
Journal Front Immunol
Date 2021 Jun 28
PMID 34177968
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Regulatory T cells (T) are key immunosuppressive cells that promote tumor growth by hindering the effector immune response. T utilize multiple suppressive mechanisms to inhibit pro-inflammatory responses within the tumor microenvironment (TME) by inhibition of effector function and immune cell migration, secretion of inhibitory cytokines, metabolic disruption and promotion of metastasis. In turn, T are being targeted in the clinic either alone or in combination with other immunotherapies, in efforts to overcome the immunosuppressive TME and increase anti-tumor effects. However, it is now appreciated that T not only suppress cells intratumorally direct engagement, but also serve as key interactors in the peritumor, stroma, vasculature and lymphatics to limit anti-tumor immune responses prior to tumor infiltration. We will review the suppressive mechanisms that T utilize to alter immune and non-immune cells outside and within the TME and discuss how these mechanisms collectively allow T to create and promote a physical and biological barrier, resulting in an immune-excluded or limited tumor microenvironment.

Citing Articles

Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review.

Tom V, Jose A, Mallick S, Sasidharan A, Pawar R, Somayaji Y Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40063239 DOI: 10.1007/s00210-025-03985-4.


Construction and verification of a prognostic model for bladder cancer based on disulfidptosis-related angiogenesis genes.

Zhou Z, Zhang Y, Zhou Y, Gu J, Li J, Shao J PeerJ. 2025; 13:e18911.

PMID: 39995998 PMC: 11849515. DOI: 10.7717/peerj.18911.


Comprehensive analysis of mitochondrial-related gene signature for prognosis, tumor immune microenvironment evaluation, and candidate drug development in colon cancer.

Wu H, Zhang W, Chang J, Wu J, Zhang X, Jia F Sci Rep. 2025; 15(1):6173.

PMID: 39979377 PMC: 11842742. DOI: 10.1038/s41598-024-85035-2.


Dysbiosis and extraintestinal cancers.

He R, Qi P, Shu L, Ding Y, Zeng P, Wen G J Exp Clin Cancer Res. 2025; 44(1):44.

PMID: 39915884 PMC: 11804008. DOI: 10.1186/s13046-025-03313-x.


Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment.

Alberti-Valls M, Olave S, Olomi A, Macia A, Eritja N Cancers (Basel). 2024; 16(23).

PMID: 39682106 PMC: 11640124. DOI: 10.3390/cancers16233918.


References
1.
Peske J, Thompson E, Gemta L, Baylis R, Fu Y, Engelhard V . Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat Commun. 2015; 6:7114. PMC: 4435831. DOI: 10.1038/ncomms8114. View

2.
Wang H, Lee D, Peng G, Guo Z, Li Y, Kiniwa Y . Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004; 20(1):107-18. DOI: 10.1016/s1074-7613(03)00359-5. View

3.
Kumar P, Bhattacharya P, Prabhakar B . A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. J Autoimmun. 2018; 95:77-99. PMC: 6289740. DOI: 10.1016/j.jaut.2018.08.007. View

4.
Wei G, Abraham B, Yagi R, Jothi R, Cui K, Sharma S . Genome-wide analyses of transcription factor GATA3-mediated gene regulation in distinct T cell types. Immunity. 2011; 35(2):299-311. PMC: 3169184. DOI: 10.1016/j.immuni.2011.08.007. View

5.
Tanaka A, Sakaguchi S . Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019; 49(8):1140-1146. DOI: 10.1002/eji.201847659. View